Navigation

TA220 Psoriatic arthritis - golimumab: costing statement

Costing statements are used when cost impact is considered to be minimal to explain why the cost impact is not considered to be significant or when it is not possible to quantify the cost impact so no costing report or costing template have been developed.

Disclaimer
This resource is an implementation tool and should be used alongside the published guidance. The information does not supersede or replace the guidance itself.

The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to costing@nice.org.uk

This page was last updated: 20 April 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.